The serotonin precursor 5‐hydroxytryptophan delays neuromuscular disease in murine familial amyotrophic lateral sclerosis

References

• Dierssen M, Fillat C, Crnic L et al. Murine models for Down syndrome. Physiol Behav 2001; 73: 859–871.
   Google Scholar
• Lejeune JM, Gautier M, Turpin R. Study of the somatic chromosomes of nine mongolian children. C R Hebd Seances Acad Sci Paris 1959; 248: 1712–1722.
   PubMedGoogle Scholar
• Epstein CJ, Avraham KB, Lovett M et al. Transgenic mice with increased Cu/Zn superoxide dismutase activity: animal model of dosage effects in Down syndrome. PNAS USA 1987; 84: 8044–8048.
   Google Scholar
• Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772–1775.
   Google Scholar
• Avraham KB, Schickler M, Sapoznikov D et al. Down syndrome: abnormal neuromuscular junction in tongue of transgenic mice with elevated levels of human Cu/Zn superoxide dismutase. Cell 1988; 54: 823–829.
   Google Scholar
• Avraham KB, Sugarman H, Rotshenker S, Groner Y. Down syndrome: morphological remodelling and increased complexity in the neuromuscular junction of transgenic Cu/Zn superoxide dismutase mice. J Neurocyto 1991; 20: 208–215.
   PubMedGoogle Scholar
• Minc-Golomb D, Knobler H, Groner Y. Gene dosage of Cu/Zn SOD and Down syndrome: diminished prostaglandin synthesis in human trisomy 21 transfected cells and transgenic mice. EMBO J 1991; 10: 2119–2124.
   PubMed Web of Science ®Google Scholar
• Peled-Kamar M, Lotem J, Okon E et al. Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn superoxide dis- mutase: implications for Down syndrome. EMBO J 1995; 14: 4985–4993.
   Google Scholar
• Gahtan E, Auerbach JM, Groner Y, Segal M. Reversible impairment of long-term potentiation in transgenic Cu/Zn SOD mice. Eur J Neurosci 1998; 10: 538–544.
   PubMed Web of Science ®Google Scholar
• Schickler M, Knobler H, Avraham KB et al. Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn superoxide dismutase activity. EMBO J 1989; 8: 1385–1392.
   PubMed Web of Science ®Google Scholar
• Rosner F, Ong BH, Paine RS, Mahanand D. Blood-serotonin activity in trisomic and translocation Down syndrome. Lancet 1965; 1(7397): 1191–1193.
   PubMed Web of Science ®Google Scholar
• Elroy-Stein O, Bernstein Y, Groner Y. Overproduction of human Cu/Zn superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J 1986; 5: 615–622.
   PubMed Web of Science ®Google Scholar
• Elroy-Stein O, Groner Y. Impaired neurotransmitter uptake in PC12 cells overexpressing human Cu/Zn superoxide dismutase: implication for gene dosage effects in Down syndrome. Cell 1988; 52: 259–267.
   PubMed Web of Science ®Google Scholar
• Bedard PJ, Tremblay LE, Barbeau H et al. Action of 5-hydroxytryptamine, substance P, thyrotrophin-releasing hormone and clonidine on motor neurone excitability. Can J Neurol Sci 1987; 14: 506–509.
   Google Scholar
• Bazelon M, Paine RS, Cowie VA et al. Reversal of hypotonia in infants with Down syndrome by administration of 5-hydroxytryptophan. Lancet 1967; 1(7500): 1130–1133.
   Google Scholar
• Coleman M. Infantile spasms associated with 5- hydroxytryptophan administration in patients with Down syndrome. Neurology 1971; 21: 911–919.
   PubMed Web of Science ®Google Scholar
• Jacobs BL. An animal behavior model for studying central serotonergic synapses. Life Sci 1976; 19: 777–786.
   PubMed Web of Science ®Google Scholar
• Rowland LP, Shneider MD. Amyotrophic lateral sclerosis. New Engl J Med 2001; 344: 1688–1700.
   PubMed Web of Science ®Google Scholar
• Sofic E, Riederer P, Gsell W et al. Biogenic amines and metabolites in spinal cord of patients with Parkinson’s disease and amyotrophic lateral sclerosis. J Neural Transm Park Dis Dement Sect 1991; 3: 133–142.
   Google Scholar
• Forrest V, Ince P, Leitch M et al. Serotonergic neurotransmission in the spinal cord and motor cortex of patients with motor neuron disease and controls: quantitative autoradiography for 5-HT1a and 5-HT2 receptors. J Neurol Sci 1996; 139 (suppl): 83–90.
   Google Scholar
• Rosen DR, Siddique T, Patterson D. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyo- trophic lateral sclerosis. Nature 1993; 362: 59–62.
   PubMed Web of Science ®Google Scholar
• Rao GH, White JG, Jachimowicz AA, Witkop CJ. An improved method for the extraction of endogenous platelet serotonin. J Lab Clin Med 1976; 87: 129–137.
   PubMed Web of Science ®Google Scholar
• Stone TW. Endogenous neurotoxins from tryptophan. Toxicon 2001; 39: 61–73.
   PubMed Web of Science ®Google Scholar
• Manaker S, Caine SB, Winokur A. Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis. Neurology 1988; 38: 1464–1474.
   PubMed Web of Science ®Google Scholar
• Engel WK, Siddique T, Nicoloff JT. Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone. Lancet 1983; 2(8341): 73–75.
   PubMed Web of Science ®Google Scholar
• Mendell JR, Chase TN, Engel WK. Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-Dopa. Trans Am Neurol Ass 1971; 96: 284–6.
   PubMedGoogle Scholar
• Ohsugi K, Adachi K, Mukoyama M, Ando K. Lack of change in indoleamine metabolism in spinal cord of patients with amyotrophic lateral sclerosis. Neurosci Lett 1987; 79: 351–354.
   PubMed Web of Science ®Google Scholar
• Bertel O, Malessa S, Sluga E, Hornykiewicz O. Amyotrophic lateral sclerosis: changes of noradrenergic and serotonergic transmitter systems in the spinal cord. Brain Res 1991; 566: 54–60.
   PubMed Web of Science ®Google Scholar